H.C. Wainwright raised the firm’s price target on Immix Biopharma (IMMX) to $8 from $7 and keeps a Buy rating on the shares after the company received a strategic investment from Goose Capital and former Tanox CEO Dr. Nancy Chang. The capital provides for an operational runway into Q2 of 2026 for Immix, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX: